Cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent - main trial

Conditions

Colorectal cancer Cancer Malignant neoplasm of colon

John Primrose, S. Pugh, Gareth J. Thomas, Matthew J. Ellis, Karwan Moutasim et al. (6 authors)

Health Technology Assessment2021-01-011 citations

A randomised controlled trial to assess the cost-effectiveness of intensive versus no scheduled follow-up in patients who have undergone resection for colorectal cancer with curative intent.

Mant D, Gray A, Pugh S, Campbell H, George S, Fuller A, Shinkins B, Corkhill A, Mellor J, Dixon E, Little L, Perera-Salazar R, Primrose J.

2017-05-0143 citations

10.3310/hta21320

Interventions

Monitoring of carcinoembryonic antigen (CEA) in primary care vs intensive imaging in hospital. Patients randomised to 1 of 4 arms: Arm 1: Symptomatic follow-up in prim

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have undergone resection for colorectal cancer with curative intent Added as of 23/01/2009: Both males and females, 50 years and older

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure amended as of 11/02/2009: Number of recurrences in each group treated surgically with curative intent, analysed at study end (5 years). Previous primary outcome measure: Overall survival by intention to treat analysis.	—

Secondary

Measure	Time frame
Current secondary outcome measures as of 11/02/2009: 1. Overall survival by intention to treat analysis, reviewed at study end (5 years) 2. Quality of life in survivors, assessed at baseline, and then at the end of study years 1-5 by the following: 2. 1. Euroqol EQ-5D 2. 2. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) 2. 3. Hospital Anxiety and Depression (HAD) scale 2. 4. Modified form of a College of Health Questionnaire 2. 5. A small number of items from the 7-item questionnaire used by Kjeldsen 3. Cost of NHS services utilised, data are collected at the end of study years 1-5 for all patients 4. NHS cost per life-year saved, assessed at study end (5 years) Previous secondary outcome measures: 1. Quality of life in survivors 2. Cost of NHS services utilised 3. NHS cost per life-years saved	—

Measure

Time frame

Current secondary outcome measures as of 11/02/2009: 1. Overall survival by intention to treat analysis, reviewed at study end (5 years) 2. Quality of life in survivors, assessed at baseline, and then at the end of study years 1-5 by the following: 2. 1. Euroqol EQ-5D 2. 2. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) 2. 3. Hospital Anxiety and Depression (HAD) scale 2. 4. Modified form of a College of Health Questionnaire 2. 5. A small number of items from the 7-item questionnaire used by Kjeldsen 3. Cost of NHS services utilised, data are collected at the end of study years 1-5 for all patients 4. NHS cost per life-year saved, assessed at study end (5 years) Previous secondary outcome measures: 1. Quality of life in survivors 2. Cost of NHS services utilised 3. NHS cost per life-years saved

—

Countries

England, United Kingdom

Outcome results

None listed